Literature DB >> 33573122

Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment Modulation of Breast Cancer.

Ioana Boca Bene1, Sorin M Dudea1, Anca I Ciurea1.   

Abstract

The aim of this paper is to highlight the role of contrast-enhanced ultrasound in breast cancer in terms of diagnosis, staging and follow-up of the post-treatment response. Contrast-enhanced ultrasound (CEUS) is successfully used to diagnose multiple pathologies and has also clinical relevance in breast cancer. CEUS has high accuracy in differentiating benign from malignant lesions by analyzing the enhancement characteristics and calculating the time-intensity curve's quantitative parameters. It also has a significant role in axillary staging, especially when the lymph nodes are not suspicious on clinical examination and have a normal appearance on gray-scale ultrasound. The most significant clinical impact consists of predicting the response to neoadjuvant chemotherapy, which offers the possibility of adjusting the therapy by dynamically evaluating the patient. CEUS is a high-performance, feasible, non-irradiating, accessible, easy-to-implement imaging method and has proven to be a valuable addition to breast ultrasound.

Entities:  

Keywords:  SonoVue; breast cancer; contrast-enhanced ultrasound; neoadjuvant chemotheraphy; sentinel lymph node

Year:  2021        PMID: 33573122      PMCID: PMC7912589          DOI: 10.3390/jpm11020081

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  64 in total

1.  Evaluation of breast lesions by contrast enhanced ultrasound: qualitative and quantitative analysis.

Authors:  Caifeng Wan; Jing Du; Hua Fang; Fenghua Li; Lin Wang
Journal:  Eur J Radiol       Date:  2011-05-25       Impact factor: 3.528

2.  Meta-Analysis: Contrast-Enhanced Ultrasound Versus Conventional Ultrasound for Differentiation of Benign and Malignant Breast Lesions.

Authors:  Qian Li; Min Hu; Zhikui Chen; Changtian Li; Xi Zhang; Yiqing Song; Feixiang Xiang
Journal:  Ultrasound Med Biol       Date:  2018-03-09       Impact factor: 2.998

3.  Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: The correlation with pathological prognostic factors.

Authors:  Chen-Li Ji; Xiao-Long Li; Ya-Ping He; Dan-Dan Li; Xin-Gang Gu; Hui-Xiong Xu
Journal:  Clin Hemorheol Microcirc       Date:  2017       Impact factor: 2.375

4.  Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.

Authors:  T M Breslin; L Cohen; A Sahin; J B Fleming; H M Kuerer; L A Newman; E S Delpassand; R House; F C Ames; B W Feig; M I Ross; S E Singletary; A U Buzdar; G N Hortobagyi; K K Hunt
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

5.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

6.  Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Ariel Saracco; Botond K Szabó; Ervin Tánczos; Jonas Bergh; Thomas Hatschek
Journal:  Acta Radiol       Date:  2016-07-28       Impact factor: 1.990

7.  Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Authors:  Giulia Galli; Giacomo Bregni; Stefano Cavalieri; Luca Porcu; Paolo Baili; Amash Hade; Francesca Di Salvo; Milena Sant; Roberto Agresti; Massimiliano Gennaro; Secondo Folli; Maria C De Santis; Biagio Paolini; Maria L Carcangiu; Filippo de Braud; Serena Di Cosimo
Journal:  Breast Care (Basel)       Date:  2017-12-12       Impact factor: 2.860

8.  Contrast-Enhanced Ultrasound for Early Prediction of Response of Breast Cancer to Neoadjuvant Chemotherapy.

Authors:  Youn Joo Lee; Sung Hun Kim; Bong Joo Kang; Yun Ju Kim
Journal:  Ultraschall Med       Date:  2018-08-13       Impact factor: 6.548

9.  Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis.

Authors:  Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430

10.  Contrast-enhanced ultrasound for evaluating the pathologic response of breast cancer to neoadjuvant chemotherapy: A meta-analysis.

Authors:  Kun Jia; Li Li; Xiao Jing Wu; Mei Jin Hao; Hong Yuan Xue
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

View more
  3 in total

1.  Analysis on factors behind sentinel lymph node metastasis in breast cancer by color ultrasonography, molybdenum target, and pathological detection.

Authors:  Aibibai Yiming; Muhetaer Wubulikasimu; Nuermaimaiti Yusuying
Journal:  World J Surg Oncol       Date:  2022-03-08       Impact factor: 2.754

2.  Contrast-enhanced ultrasound of breast tumors: an initial experience.

Authors:  Merete U Kristiansen; Marit A Martiniussen; Anne Sofie F Larsen
Journal:  Acta Radiol Open       Date:  2022-04-28

3.  Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.

Authors:  Xue Han; Shiyang Jin; Huajing Yang; Jinxing Zhang; Zhenfeng Huang; Jiguang Han; Chuan He; Hongyan Guo; Yue Yang; Ming Shan; Guoqiang Zhang
Journal:  Br J Radiol       Date:  2021-09-01       Impact factor: 3.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.